english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Updated list of "Drugs to avoid, in the name of better patient care" is published by independent French journal Prescrire

Prescrire "Drugs to avoid" The independent French medical journal Prescrire has published its annual review of "Drugs to avoid", identifying drugs that are clearly more harmful than beneficial. The full report will be published in English in the February 2020 issue of Prescrire International.
1 December 2019

Emicizumab (Hemlibra°) in haemophilia A. A first-choice preventive treatment for patients with factor VIII inhibitors

FEATURED REVIEW Prescrire's editors have rated emicizumab prophylaxis in patients with haemophilia A in whom factor VIII is no longer effective due to the development of factor VIII inhibitors "a real advance". Reduced incidence of bleeding and greater convenience should be weighed against the lack of long-term data, the lack of evaluation in certain clinical situations, and the risk of thrombosis.
Full review (2 pages) available for download by subscribers.
1 December 2019

In the December issue of Prescrire International: pertuzumab (Perjeta°) after surgery for some breast cancers at high risk of recurrence

FREE DOWNLOAD Pertuzumab (Perjeta°) is a monoclonal antibody which has been authorised for use after surgery for some breast cancers. How do Prescrire's editors rate the drug's harm-benefit balance in this situation, in light of the most recent evidence?
Full text available for free download.
1 December 2019

The Mediator° disaster: so much time wasted, so many lives destroyed

1 December 2019

Diclofenac: a habit that needs changing

Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), is routinely used, despite evidence of a greater risk of adverse cardiovascular events when compared with other NSAIDs such as ibuprofen or naproxen, whereas it offers no additional benefit.
1 December 2019

Anti-inflammatory drugs: risks for the kidneys even in young, healthy adults

Taking nonsteroidal anti-inflammatory drugs (NSAIDs) presents risks of nephrotoxicity in young people during intense physical exercise, especially in hot weather.
1 December 2019

Sore throat: paracetamol is the best option

Nonsteroidal anti-inflammatory drugs (NSAIDs) appear to be somewhat more effective than paracetamol, but they expose patients to more serious side effects.
1 December 2019

Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection

FEATURED REVIEW First-line therapy for patients with HIV infection is usually based on triple therapy. When sustained virological suppression has been achieved, treatment "simplification" can sometimes be considered. Is the two-drug regimen dolutegravir + rilpivirine (Juluca°) any better than other treatment options?
Full review (3 pages) available for download by subscribers.
1 November 2019

In the November issue of Prescrire International - Gliptins: joint pain and exposure to NSAIDs

FREE DOWNLOAD In the Adverse Effects section of the November issue, the results of a study by the independent French medical journal Prescrire, based on data from France's national health insurance system.
Full text available for free download.
1 November 2019

Gemtuzumab ozogamicin (Mylotarg°) in acute myeloid leukaemia: no proven benefits

According to currently available clinical evaluation data, gemtuzumab ozogamicin (Mylotarg°) does not provide tangible benefits for patients with acute myeloid leukaemia.
1 November 2019

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90